NetraMark Holdings (TSE:AIAI) has released an update.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NetraMark Holdings is set to revolutionize clinical trials with its new Treatment Attitude Profile (TAP™) scale, unveiled at the ASCP Annual Meeting. The scale, powered by NetraMark’s NetraAI technology, identifies placebo responders, enhancing trial design and patient selection. This innovation promises to reduce time, cost, and failure rates in psychiatric clinical trial development, marking a significant step forward in treatment efficacy discovery.
For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.